Study Details
Design, interventions, and primary outcomes
About This Study
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.
Design
Interventions / Regimen
- Drug: Induction therapy — 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
Primary Outcomes
- Progression-free survival (PFS) * (2 years)
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-13
Completion: 2028-09-30
Sex: ALL
Volunteers: false
Enrollment: 106 (ESTIMATED)
Collaborators: Chugai Pharmaceutical
- Drug: Induction therapy — 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX